Parkinson’s Illness: Primary information.
Med Monatsschr Pharm. 2016 Jul;39(7):277-81
Authors: Rose O
Pharmacotherapy in Parkinson’s illness is advanced and requires experience in all health-care professions. In addition to idiopathic Parkinson’s illness (IPD) secondary parkinsonism, monogenetic Parkinson’s illness and atypical syndromes have to be differentiated. The prevalence within the European inhabitants is estimated to be roughly 1 %. Life-style and age are carefully linked to IPD. Neurodegeneration with formation of Lewy-bodies and elevated oxidative stress within the pars compacta of the substantia nigra are carefully linked to IPD. Lewy-bodies present misfolded ?-Synuclein. The stability of glutamate, GABA and dopamine is important for motor problems. Bradykinesia/akinesia, rigidity, relaxation tremor and postural instability are typical signs together with dissymmetry, shuffling gait and camptocormia, micrographia, aphasia, hypophonia, dysphagia, and hypomimia. Early signs are akathisia/restlessness, insomnia, somnolence, hyposmia and neck ache. With additional development of IPD, neurons of the ventral tegmental space are affected and result in non-motor signs, which therefore are instantly associated to the underlying illness. Gastric dysmotility, despair, urinary incontinence, extreme sweating, hallucinations, spasticity, muscle ache and Parkinson’s illness dementia are a part of IPD.
PMID: 29953178 [PubMed – indexed for MEDLINE]